We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Highlights Range of Automatic Diagnostic Analyzers at MEDICA 2022

By LabMedica International staff writers
Posted on 14 Nov 2022

Randox Laboratories (Crumlin, UK) is highlighting its extensive range of diagnostic analyzers at this year's MEDICA, the world's largest annual medical technology trade fair taking place from 14-17 November in Düsseldorf, Germany. More...

Among its innovative products being presented by Randox at MEDICA 2022 is the RX misano, a high performance semi-automated clinical chemistry analyzer. The RX misano shines a new light on semi-automated clinical chemistry testing with increased auto-functionality and groundbreaking technology and is capable of high standard, precise results at a competitive price per test. It expands testing capabilities with the ability to run both routine and specialized tests including chemistries, specific proteins, antioxidants, veterinary and diabetes testing, and can analyze a variety of sample types, including serum, plasma, and urine.

Randox is also exhibiting the RX monaco which comprises an extensive test menu covering routine chemistries, specific proteins, lipids, antioxidants, diabetes and veterinary testing with emergency and STAT sampling. The RX monaco is ideal for low to mid volume clinical chemistry testing consolidating routine and specialized testing on one efficient and easy to use platform. Offering the ultimate in convenience, performance and confidence, the RX monaco is capable of performing 170 photometric tests per hour. The RX monaco combines robust hardware and intuitive software offering customers choice to suit their unique circumstances, where they can choose between a benchtop or floor standing system.

Also on display at the Randox booth at MEDICA 2022 is the RX daytona+ fully automated analyzer which can perform a wide range of niche and specialized routine chemistries, specific proteins, lipids, therapeutic drugs, antioxidants, diabetes and veterinary testing. The RX daytona+ also has direct HbA1c testing capabilities, eliminating sample pre-dilution and ultimately saving time in the laboratory, and can analyze a variety of sample types including serum, plasma urine, CSF and whole blood. The fully automated, random access platform can deliver a high level of precision, accuracy and reliability with the ability to perform emergency STAT sampling. The most versatile analyzer in its class, the RX daytona+ is capable of performing 270 photometric tests per hour and up to 450 tests per hour with ISE.

Related Links:
Randox Laboratories


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
New
See-Saw Rocking Shaker
SH-200D-S-L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A blood-based test aims to address gaps in population-level early cancer detection (Photo courtesy of Harbinger Health)

Blood-Based MCED Test Enables Early-Stage Detection for Multiple Cancer Types

Around 84,000 new cancer cases in the United States each year are thought to arise from obesity, and over the past two decades, the rate of obesity-related cancers has climbed markedly. Thirteen malignancies... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.